Spire Healthcare Group/£SPI
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Spire Healthcare Group
Spire Healthcare Group PLC, listed under the ticker SPI, is a prominent provider of private healthcare in the United Kingdom. The company operates a network of private hospitals and clinics offering comprehensive treatment options spanning various medical fields. Founded in 2007, Spire Healthcare has established a reputation for clinical excellence and responsive patient care.
- Ticker
- £SPI
- Sector
- Health
- Primary listing
- LSE
- Employees
- 17,800
- Headquarters
- London, United Kingdom
- Website
- www.spirehealthcare.com
SPI Metrics
BasicAdvanced
£997M
-
-£0.00
0.88
£0.02
0.60%
Price and volume
Market cap
£997M
Beta
0.88
52-week high
£2.50
52-week low
£1.41
Average daily volume
2.2M
Dividend rate
£0.02
Financial strength
Current ratio
0.596
Quick ratio
0.37
Long term debt to equity
1.647
Total debt to equity
1.798
Interest coverage (TTM)
1.15%
Profitability
EBITDA (TTM)
191.7
Gross margin (TTM)
45.20%
Net profit margin (TTM)
-0.12%
Operating margin (TTM)
7.64%
Effective tax rate (TTM)
81.43%
Revenue per employee (TTM)
£90,000
Management effectiveness
Return on assets (TTM)
3.19%
Return on equity (TTM)
-0.18%
Valuation
Price to revenue (TTM)
0.632
Price to book
1.38
Price to tangible book (TTM)
3.51
Price to free cash flow (TTM)
5.679
Free cash flow yield (TTM)
17.61%
Free cash flow per share (TTM)
0.438
Dividend yield (TTM)
0.60%
Growth
Revenue change (TTM)
1.97%
Earnings per share change (TTM)
-110.37%
3-year revenue growth (CAGR)
7.26%
10-year revenue growth (CAGR)
5.71%
3-year earnings per share growth (CAGR)
-54.68%
10-year earnings per share growth (CAGR)
-29.66%
3-year dividend per share growth (CAGR)
44.23%
10-year dividend per share growth (CAGR)
-8.63%
What the Analysts think about SPI
Analyst ratings (Buy, Hold, Sell) for Spire Healthcare Group stock.
Analyst projections of the future price of Spire Healthcare Group stock.
Bulls say / Bears say
A recommended cash offer of 250p a share values Spire at a 66.2% premium to its 13 May price. Shareholders approved the scheme on 30 October, reducing execution uncertainty, although regulatory approval and court sanction remain outstanding. (Investegate, FCA)
Private-pay growth is helping Spire rely less on NHS activity: first-half self-pay revenue rose 4.5%, PMI revenue rose 3.1%, and primary-care revenue rose 8.1%. A new four-year Bupa partnership adds planned cancer, musculoskeletal and women’s health pathways. (Investegate)
First-half adjusted free cash flow rose 35.3% to £20.7m and cash conversion improved to 110.6%. That stronger cash generation offers some financial flexibility as Spire continues to invest and manage its debt. (Investegate)
First-half NHS revenue fell 14.3%, pulling group adjusted EBITDA down 16.6% to £112.4m and leaving Spire with a £14.8m statutory pre-tax loss. Private growth did not fully make up for the lost NHS activity. (Investegate)
Cost pressure is squeezing returns: adjusted operating costs rose 7.4%, while the operating margin fell to 4.8% from 7.9%. Leverage also increased to 2.4 times from 2.0 times at year-end as earnings weakened. (Investegate)
Recent CQC findings point to clinical-governance and reputation risks at individual sites. London East was rated “requires improvement” for leadership, while South Bank temporarily suspended some imaging services after inspection concerns, although the provider acted on those findings. (Care Quality Commission, Care Quality Commission)
Data summarised monthly by Lightyear AI. Last updated on 31 Oct 2026.
SPI Financial Performance
Revenues and expenses
SPI Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing SPI
AllGBPUSDEUR
Fund name | Fund size | £SPI weighting |
|---|---|---|
iShares FTSE 250£MIDD | £672M | 0.21% |
Vanguard FTSE 250£VMIG | £569M | 0.21% |
Vanguard FTSE 250£VMID | £1.5B | 0.21% |
iShares Ageing Population$AGED | $953M | 0.08% |
iShares Ageing Population€AGED | $903M | 0.08% |
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by London Stock Exchange, through Infront.